CAPTRUST Financial Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$138K	Buy	37,672 +18,774	+99%	+$62.5K	﹤0.01%	2976
2026 Q1	$58K	Buy	18,898 +1,790	+10%	+$6.92K	﹤0.01%	2886
2025 Q4	$70K	Buy	+17,108	New	+$84.7K	﹤0.01%	2649
2024 Q1	–	Sell	-419,721	Closed	-$4.14M	–	2570
2023 Q4	$4.14M	Buy	419,721 +6,407	+2%	+$45.7K	0.01%	615
2023 Q3	$3.16M	Buy	+413,314	New	+$4.12M	0.01%	679
2022 Q2	–	Sell	-161	Closed	-$1K	–	5109
2022 Q1	$1K	Buy	161 +141	+705%	+$1.5K	﹤0.01%	4738
2021 Q4	$0	Buy	+20	New	+$376	﹤0.01%	4890

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CAPTRUST Financial Advisors's RXRX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 99% in Q2 2026, buying an estimated $62.5K and bringing the position to 37,672 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

CAPTRUST Financial Advisors first reported a position in RXRX in Q4 2021 and has held it in 7 quarters since. The position peaked at $4.14M in Q4 2023. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

CAPTRUST Financial Advisors held 37,672 shares of Recursion Pharmaceuticals worth $138K as of Q2 2026.
CAPTRUST Financial Advisors bought 18,774 Recursion Pharmaceuticals shares in Q2 2026, an estimated $62.5K.
Recursion Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2976 holding.
CAPTRUST Financial Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 7 quarters since.
CAPTRUST Financial Advisors's Recursion Pharmaceuticals position peaked at $4.14M in Q4 2023.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.